These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Serum sclerostin decreases following 12months of resistance- or jump-training in men with low bone mass. Hinton PS; Nigh P; Thyfault J Bone; 2017 Mar; 96():85-90. PubMed ID: 27744012 [TBL] [Abstract][Full Text] [Related]
44. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Pietrzyk B; Smertka M; Chudek J Adv Clin Exp Med; 2017 Nov; 26(8):1283-1291. PubMed ID: 29264888 [TBL] [Abstract][Full Text] [Related]
45. Sclerostin: a possible target for the management of cancer-induced bone disease. Gkotzamanidou M; Dimopoulos MA; Kastritis E; Christoulas D; Moulopoulos LA; Terpos E Expert Opin Ther Targets; 2012 Aug; 16(8):761-9. PubMed ID: 22762409 [TBL] [Abstract][Full Text] [Related]
46. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318 [TBL] [Abstract][Full Text] [Related]
47. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. Gennari L; Merlotti D; Valenti R; Ceccarelli E; Ruvio M; Pietrini MG; Capodarca C; Franci MB; Campagna MS; Calabrò A; Cataldo D; Stolakis K; Dotta F; Nuti R J Clin Endocrinol Metab; 2012 May; 97(5):1737-44. PubMed ID: 22399511 [TBL] [Abstract][Full Text] [Related]
48. Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus. Catalano A; Pintaudi B; Morabito N; Di Vieste G; Giunta L; Bruno ML; Cucinotta D; Lasco A; Di Benedetto A Eur J Endocrinol; 2014 Sep; 171(3):293-300. PubMed ID: 24891138 [TBL] [Abstract][Full Text] [Related]
49. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929 [TBL] [Abstract][Full Text] [Related]
50. Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. Yavropoulou MP; van Lierop AH; Hamdy NA; Rizzoli R; Papapoulos SE Bone; 2012 Jul; 51(1):153-7. PubMed ID: 22579776 [TBL] [Abstract][Full Text] [Related]
51. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients. Jean G; Chazot C; Bresson E; Zaoui E; Cavalier E Nephron; 2016; 132(3):181-90. PubMed ID: 26890570 [TBL] [Abstract][Full Text] [Related]
52. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083 [TBL] [Abstract][Full Text] [Related]
53. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336 [TBL] [Abstract][Full Text] [Related]
54. Sclerostin declines during hemodialysis and appears in Dialysate. Bielesz BO; Hempfing T; Kieweg H; Marculescu R; Haas M; Cejka D Blood Purif; 2014; 38(1):30-6. PubMed ID: 25228355 [TBL] [Abstract][Full Text] [Related]
55. [Sclerostin: a new biomarker of interest in nephrology]. Pelletier S; Jean G; Fouque D; Ann Biol Clin (Paris); 2015; 73(3):305-13. PubMed ID: 26069067 [TBL] [Abstract][Full Text] [Related]
56. Serum sclerostin levels following treatment with parathyroid hormone. Polyzos SA; Anastasilakis AD; Terpos E J Endocrinol Invest; 2013 Apr; 36(4):280. PubMed ID: 23645100 [No Abstract] [Full Text] [Related]
57. Differential sclerostin and parathyroid hormone response to exercise in boys and men. Falk B; Haddad F; Klentrou P; Ward W; Kish K; Mezil Y; Radom-Aizik S Osteoporos Int; 2016 Mar; 27(3):1245-1249. PubMed ID: 26361948 [TBL] [Abstract][Full Text] [Related]
58. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202 [TBL] [Abstract][Full Text] [Related]
59. Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions. Newman CL; Chen NX; Smith E; Smith M; Brown D; Moe SM; Allen MR Bone; 2015 Aug; 77():50-6. PubMed ID: 25892482 [TBL] [Abstract][Full Text] [Related]
60. Relationship between endogenous parathyroid hormone and bone metabolism/geometry in female patients treated with glucocorticoid. Kaji H; Yamauchi M; Chihara K; Sugimoto T Horm Metab Res; 2008 Jan; 40(1):60-5. PubMed ID: 18072075 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]